display
Washington / Cambridge (dpa) - The US health authority NIAID has expressed doubts about the informative value of data from a new study by the pharmaceutical company Astrazeneca on its vaccine.
This involves the results of a so-called phase III study with around 32,500 test subjects, which, according to the manufacturer, show that the vaccine is highly effective.
In its statement, the NIAID does not doubt earlier studies, which also speak in favor of a good effectiveness of the preparation.
"The DSMB has expressed concern that Astrazeneca may have included out of date information from this study, which may have provided an incomplete view of the efficacy data," said the National Institute for Infectious Diseases (NIAID) on Monday (local time), citing the Data Monitoring Committee and Safety Monitoring Board (DSMB) with.
The company needs to review the data and ensure that the most accurate and up-to-date effectiveness data is published as soon as possible.
display
Astrazeneca announced on Monday that a phase III study with around 32,500 subjects in the USA, Chile and Peru had confirmed the high effectiveness of the corona vaccine.
The vaccine protects against Covid-19 with an effectiveness of 79 percent, for people over 65 this value is 80 percent.
This means that 80 percent fewer diseases occurred among the older subjects in a vaccinated group than among those in a control group.
The effectiveness across all age groups in relation to severe disease courses is even 100 percent.
Even before, studies had independently certified that the vaccine was highly effective.
The British-Swedish company developed the vaccine called AZD1222 together with Oxford University.
It has been used on a large scale in the UK since January.
Germany and several other countries had suspended the vaccination with the Astrazeneca substance for the time being because several cases of thrombosis (blood clots) in the cerebral veins were reported in relation to the vaccination.
The vaccine is now being used again.
display
© dpa-infocom, dpa: 210323-99-934695 / 2
Astrazeneca announcement
Communication NIAID